This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

MorphoSys Valuation

Is MORD undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of MORD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate MORD's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate MORD's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for MORD?

Key metric: As MORD is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for MORD. This is calculated by dividing MORD's market cap by their current revenue.
What is MORD's PS Ratio?
PS Ratio	10.5x
Sales	€241.47m
Market Cap	€2.53b

MORD key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	17.1x
Enterprise Value/EBITDA	-9.3x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does MORD's PS Ratio compare to its peers?

The above table shows the PS ratio for MORD vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	7x
GNS Genus	1.7x	3.5%	UK£1.1b
OXB Oxford Biomedica	4.6x	21.0%	UK£447.8m
BVXP Bioventix	14.5x	n/a	UK£197.0m
AVCT Avacta Group	7.4x	0.4%	UK£168.3m
MORD MorphoSys	10.5x	25.0%	€2.5b

Price-To-Sales vs Peers: MORD is expensive based on its Price-To-Sales Ratio (10.5x) compared to the peer average (8.2x).

Price to Sales Ratio vs Industry

How does MORD's PS Ratio compare vs other companies in the GB Biotechs Industry?

6 Companies	Price / Sales	Estimated Growth	Market Cap
GNS Genus	1.7x	3.5%	US$1.42b
OXB Oxford Biomedica	4.6x	21.0%	US$567.59m
TRX Tissue Regenix Group	1.6x	15.1%	US$51.92m
PBX ProBiotix Health	3.7x	n/a	US$10.02m

6 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: MORD is expensive based on its Price-To-Sales Ratio (10.5x) compared to the European Biotechs industry average (9.5x).

Price to Sales Ratio vs Fair Ratio

What is MORD's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

MORD PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	10.5x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate MORD's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Formycon

€857.2m

A biotechnology company, develops biosimilar drugs in Germany and Switzerland.

0W4N

€48.65

3.6%

-24.5%

hVIVO

UK£144.6m

Operates as a pharmaceutical service and contract research company in the United Kingdom.

HVO

UK£0.21

-3.8%

4.9%

Laboratorios Farmaceuticos Rovi

€3.3b

Engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally.

0ILL

€64.00

3.6%

15.7%